Literature DB >> 27072198

Polymeric Nanogels with Tailorable Degradation Behavior.

Yinan Chen1, Mies J van Steenbergen1, Dandan Li1, Joep B van de Dikkenberg1, Twan Lammers1,2,3, Cornelus F van Nostrum1, Josbert M Metselaar2,3, Wim E Hennink1.   

Abstract

The aim of this study is to design a polymeric nanogel system with tailorable degradation behavior. To this end, hydroxyethyl methacrylate-oligoglycolates-derivatized poly(hydroxypropyl methacrylamide) (pHPMAm-Gly-HEMA) and hydroxyethyl methacrylamide-oligoglycolates-derivatized poly(hydroxyethyl methacrylamide) (pHEMAm-Gly-HEMAm) are synthesized and characterized. pHEMAm-Gly-HEMAm shows faster hydrolysis rates of both carbonate and glycolate esters than the same ester groups of pHPMAm-Gly-HEMA. pHEMAm-Gly-HEMAm nanogels have tailorable degradation kinetics from 24 h to more than 4 d by varying their crosslink densities. It is shown that the release of a loaded macromolecular model drug is controlled by degradation of nanogels. The nanogels show similar cytocompatibility as PLGA nanoparticles and are therefore considered to be attractive systems for drug delivery.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  biodegradable; crosslink density; cytocompatibility; drug delivery systems; polymeric nanogels

Mesh:

Substances:

Year:  2016        PMID: 27072198     DOI: 10.1002/mabi.201600031

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN: 1616-5187            Impact factor:   4.979


  2 in total

1.  Dual-responsive degradable core-shell nanogels with tuneable aggregation behaviour.

Authors:  Dominic M Gray; Adam R Town; Edyta Niezabitowska; Steve P Rannard; Tom O McDonald
Journal:  RSC Adv       Date:  2022-01-13       Impact factor: 3.361

2.  A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase.

Authors:  Helena C Besse; Yinan Chen; Hans W Scheeren; Josbert M Metselaar; Twan Lammers; Chrit T W Moonen; Wim E Hennink; Roel Deckers
Journal:  Pharmaceutics       Date:  2020-06-10       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.